JoinClinicalTrials.com

Results

Hot

Post your clinical trial on JoinClinicalTrials.com

Ellijay, Georgia 30536
United States

Post your clinical trial on JoinClinicalTrials.com to reach thousands of viewer daily. Our Clinical Trial Listings have consistently proven to be an ...

• Neural Indices of Intervention Outcomes in Children With Speech Sound Disorders

  NCT03623100

  Condition:   Speech Sound Disorder
  Interventions:   Behavioral: Speech Production Treatment.;   Behavioral: Speech Production + Speech Perception Treatment.
  Sponsors:   Idaho State University;   National Institute on Deafness and Other Communication Disorders (NIDCD)
  Recruiting
• Omegaven Expanded Access Protocol

  NCT02121769

  Condition:   Parenteral Nutrition Associated Liver Disease
  Intervention:   Drug: Omegaven
  Sponsor:   St. Luke’s Health System, Boise, Idaho
  No longer available
• Efficacy of a Web-Based Alcohol Intervention for High School Students

  NCT03613818

  Condition:   Underage Drinking
  Intervention:   Behavioral: eCHECKUP TO GO
  Sponsors:   Boise State University;   National Institutes of Health (NIH);   National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  Completed
• McNeel Eye Center Corneal Crosslinking Study

  NCT02921009

  Condition:   Keratoconus
  Intervention:   Device: Crosslinking using UV light of two different fluence rates
  Sponsor:   McNeel Eye Center
  Recruiting
• Scaling up Schoolwide Positive Behavioral Interventions and Supports (SWPBIS) in Rural Idaho Schools

  NCT03736395

  Condition:   Problem Behavior
  Interventions:   Behavioral: Idaho Rural Implementation Model;   Behavioral: Control
  Sponsors:   Boise State University;   U.S. Department of Justice
  Recruiting
• A Post-Market Retrospective Study on Revision Total Knee Arthroplasty Using Medacta GMK® Revision Prosthesis

  NCT02912351

  Condition:   Osteoarthritis
  Intervention:   Other: Patient record review, Radiographs, and questionaires.
  Sponsor:   Medacta USA
  Recruiting
• Integrating Care After Exacerbation of COPD

  NCT02021955

  Condition:   Chronic Obstructive Pulmonary Disease
  Intervention:   Behavioral: guideline treatment recommendations
  Sponsor:   VA Office of Research and Development
  Completed
• Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

  NCT04056299

  Condition:   Hen Egg Allergy
  Interventions:   Biological: AR201 Powder;   Biological: Placebo powder
  Sponsor:   Aimmune Therapeutics, Inc.
  Recruiting
• FreeStyle LIbre Flash Glucose Monitoring System Pediatric Accuracy Study

  NCT03820050

  Condition:   Diabetes Mellitus
  Intervention:   Device: Freestyle LIbre Flash Glucose Monitoring System
  Sponsor:   Abbott Diabetes Care
  Completed
• FreeStyle Libre Flash Glucose Monitoring System Post Approval Study for Pediatric Patients

  NCT03448367

  Condition:   Diabetes Mellitus
  Intervention:   Device: FreeStyle Libre Flash Glucose Monitoring System
  Sponsor:   Abbott Diabetes Care
  Recruiting
• Dextromethorphan Pediatric Acute Cough Study

  NCT02651116

  Condition:   Cough
  Interventions:   Drug: Dextromethorphan Hydrobromide;   Drug: Placebo;   Device: Cough recording device
  Sponsor:   Pfizer
  Recruiting
• A Multi-centre, Prospective Surveillance to Assess Mid-term Performance of the Mpact Cup

  NCT02196818

  Conditions:   Osteoarthritis;   Arthritis;   Avascular Necrosis;   Fracture of the Femoral Neck or Head;   Congenital Hip Dysplasia
  Intervention:   Device: Mpact Acetabular Shell
  Sponsor:   Medacta International SA
  Recruiting
• Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

  NCT03656510

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Drug: JNJ-53718678;   Drug: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

  NCT03740919

  Condition:   Type 1 Diabetes Mellitus
  Interventions:   Drug: LY900014;   Drug: Insulin Lispro
  Sponsor:   Eli Lilly and Company
  Recruiting
• An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation

  NCT03120520

  Condition:   Chronic Idiopathic Constipation
  Interventions:   Drug: Plecanatide;   Drug: Matching placebo
  Sponsor:   Bausch Health Americas, Inc.
  Completed
• Study of Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler

  NCT02980133

  Condition:   Asthma
  Interventions:   Drug: Fp MDPI;   Drug: FS MDPI;   Drug: Placebo
  Sponsor:   Teva Branded Pharmaceutical Products, R&D Inc.
  Completed
• Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid® Both in Combination With Insulin Degludec in Children and Adolescents With Type 1 Diabetes

  NCT02670915

  Conditions:   Diabetes;   Diabetes Mellitus, Type 1
  Interventions:   Drug: Faster-acting insulin aspart;   Drug: insulin aspart;   Drug: insulin degludec
  Sponsor:   Novo Nordisk A/S
  Completed
• A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth

  NCT01146990

  Condition:   Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
  Intervention:   Drug: ASQ-3, Bayley III, Neurologic exam
  Sponsors:   AMAG Pharmaceuticals, Inc.;   Registrat-Mapi
  Recruiting
• Cancer Care Delivery in Adolescent and Young Adult Patients With Acute Lymphoblastic Leukemia

  NCT03204916

  Condition:   Acute Lymphoblastic Leukemia
  Interventions:   Other: Medical Chart Review;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Active Surveillance, Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

  NCT03067181

  Conditions:   Adult Germ Cell Tumor;   Childhood Extracranial Germ Cell Tumor;   Childhood Germ Cell Tumor;   Extragonadal Embryonal Carcinoma;   Grade 2 Ovarian Teratoma;   Malignant Germ Cell Tumor;   Malignant Ovarian Teratoma;   Stage I Ovarian Choriocarcinoma;   Stage I Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage I Ovarian Teratoma AJCC v6 and v7;   Stage I Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage I Testicular Choriocarcinoma AJCC v6 and v7;   Stage I Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage I Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage II Ovarian Choriocarcinoma;   Stage II Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage II Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage II Testicular Choriocarcinoma AJCC v6 and v7;   Stage II Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage II Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage III Ovarian Choriocarcinoma;   Stage III Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage III Ovarian Yolk Sac Tumor AJCC v6 and v7;   Stage III Testicular Choriocarcinoma AJCC v6 and v7;   Stage III Testicular Embryonal Carcinoma AJCC v6 and v7;   Stage III Testicular Yolk Sac Tumor AJCC v6 and v7;   Stage IV Ovarian Choriocarcinoma;   Stage IV Ovarian Embryonal Carcinoma AJCC v6 and v7;   Stage IV Ovarian Yolk Sac Tumor AJCC v6 and v7;   Testicular Mixed Choriocarcinoma and Embryonal Carcinoma;   Testicular Mixed Choriocarcinoma and Teratoma;   Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
  Interventions:   Other: Best Practice;   Drug: Bleomycin;   Biological: Bleomycin Sulfate;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

  NCT02567435

  Conditions:   Alveolar Rhabdomyosarcoma;   Botryoid-Type Embryonal Rhabdomyosarcoma;   Embryonal Rhabdomyosarcoma;   Rhabdomyosarcoma;   Sclerosing Rhabdomyosarcoma;   Spindle Cell Rhabdomyosarcoma;   Untreated Childhood Rhabdomyosarcoma
  Interventions:   Drug: Cyclophosphamide;   Biological: Dactinomycin;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Radiation: Radiation Therapy;   Drug: Temsirolimus;   Drug: Vincristine Sulfate;   Drug: Vinorelbine
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Respiratory Syncytial Virus (RSV) Investigational Vaccine in Infants Aged 6 and 7 Months Likely to be Unexposed to RSV

  NCT03636906

  Condition:   Respiratory Syncytial Virus Infections
  Interventions:   Biological: Respiratory syncytial virus (RSV) vaccine GSK3389245A;   Biological: Bexsero;   Biological: Nimenrix;   Biological: Menveo;   Biological: Synflorix;   Drug: Placebo
  Sponsor:   GlaxoSmithKline
  Recruiting
• Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity

  NCT02918279

  Conditions:   Metabolism and Nutrition Disorder;   Obesity
  Interventions:   Drug: Liraglutide;   Drug: Placebo
  Sponsor:   Novo Nordisk A/S
  Active, not recruiting
• Low-Dose Atropine for Treatment of Myopia

  NCT03334253

  Condition:   Myopia
  Interventions:   Drug: Atropine;   Other: Placebo Eyedrops
  Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
  Recruiting
• Evaluation of SPN-812 ER Low Dose in Children With ADHD

  NCT03247530

  Condition:   ADHD
  Interventions:   Drug: Placebo;   Drug: 100mg SPN-812 ER;   Drug: 200mg SPN-812 ER
  Sponsor:   Supernus Pharmaceuticals, Inc.
  Completed
• Secukinumab Safety and Efficacy in JPsA and ERA

  NCT03031782

  Conditions:   Juvenile Psoriatic Arthritis;   Enthesitis-related Arthritis
  Interventions:   Drug: AIN457;   Other: Matched placebo
  Sponsor:   Novartis Pharmaceuticals
  Active, not recruiting
• Growth and Tolerance of Infants Fed Milk-Based Infant Formula

  NCT03967132

  Condition:   Gastro-Intestinal Tolerance
  Interventions:   Other: Control Infant Formula;   Other: Experimental Infant Formula;   Other: Reference Group
  Sponsor:   Abbott Nutrition
  Recruiting
• Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

  NCT02141074

  Conditions:   Congenital Bleeding Disorder;   Haemophilia B
  Intervention:   Drug: nonacog beta pegol
  Sponsor:   Novo Nordisk A/S
  Recruiting
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

  NCT03653364

  Condition:   Influenza
  Intervention:   Drug: Baloxavir Marboxil
  Sponsor:   Hoffmann-La Roche
  Recruiting
• Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

  NCT03875729

  Condition:   Type 1 Diabetes Mellitus
  Interventions:   Biological: teplizumab;   Biological: Placebo
  Sponsor:   Provention Bio, Inc.
  Recruiting
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

  NCT03796676

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: PF-04965842;   Drug: PF04965842
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Leuprolide Acetate 45mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)

  NCT03695237

  Condition:   Central Precocious Puberty (CPP)
  Intervention:   Drug: Leuprolide Acetate (LA)
  Sponsor:   AbbVie
  Recruiting
• Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

  NCT03629184

  Condition:   Influenza
  Interventions:   Drug: Baloxavir Marboxil;   Drug: Oseltamivir
  Sponsor:   Hoffmann-La Roche
  Completed
• Evaluation of SPN-812 ER Low Dose in Adolescents With ADHD

  NCT03247517

  Condition:   ADHD
  Interventions:   Drug: Placebo;   Drug: 200mg SPN-812 ER;   Drug: 400mg SPN-812 ER
  Sponsor:   Supernus Pharmaceuticals, Inc.
  Completed
• GlaxoSmithKline's (GSK) Safety and Immunogenicity Study of GSK Meningococcal Group B and 13-valent Pneumococcal Vaccines Administered Together With Routine Infant Vaccines in Healthy Infants

  NCT03621670

  Condition:   Infections, Meningococcal
  Interventions:   Biological: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ);   Biological: Prevnar13;   Biological: Pediarix;   Biological: Hiberix;   Biological: Rotarix;   Biological: M-M-R II;   Biological: Varivax;   Biological: Placebo (saline water)
  Sponsor:   GlaxoSmithKline
  Recruiting
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric (7-17 Years) With Major Depressive Disorder

  NCT03569475

  Condition:   Major Depressive Disorder
  Interventions:   Drug: Levomilnacipran ER;   Drug: Fluoxetine;   Drug: Placebo
  Sponsor:   Allergan
  Recruiting
• Assess the Mid-term Performance of the Mpact Cup in Subjects Requiring Total Hip Arthroplasty

  NCT03897595

  Condition:   Hip Osteoarthritis
  Intervention:   Device: Quadra®-H, Quadra®-C, AMIStem®-H or AMIStem®-C femoral stem and Mpact® Acetabular hip system with CoCr Femoral Head or Ceramic MectaCer BIOLOX® Femoral Head
  Sponsor:   Medacta USA
  Recruiting
• Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

  NCT03537508

  Condition:   Meningococcal Infections
  Interventions:   Biological: MenACYW conjugate vaccine;   Biological: MenACYW-135 conjugate vaccine;   Biological: DTaP-IPV//Hib vaccine;   Biological: Pneumococcal 13-valent conjugate vaccine;   Biological: Pentavalent rotavirus vaccine;   Biological: Hepatitis B vaccine;   Biological: Measles, mumps, rubella (MMR) vaccine;   Biological: Varicella vaccine;   Biological: Hepatitis A vaccine
  Sponsor:   Sanofi Pasteur, a Sanofi Company
  Recruiting
• Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

  NCT03429543

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Linagliptin;   Drug: Empagliflozin;   Drug: Placebo
  Sponsor:   Boehringer Ingelheim
  Recruiting
• Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

  NCT02968004

  Condition:   Pediatric Growth Hormone Deficiency
  Interventions:   Drug: MOD-4023;   Drug: Somatropin
  Sponsor:   Opko Biologics
  Active, not recruiting
• Study to Assess the Safety and Efficacy of ONZETRA® Xsail® (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

  NCT03338920

  Condition:   Acute Migraine With or Without Aura
  Interventions:   Drug: sumatriptan nasal powder;   Drug: Placebo
  Sponsor:   Avanir Pharmaceuticals
  Active, not recruiting
• Safety and Tolerability Study of SHP465 in Children Aged 4 to 12 Years Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD)

  NCT03325894

  Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
  Intervention:   Drug: SHP465
  Sponsor:   Shire
  Terminated
• Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years

  NCT03325881

  Condition:   Attention Deficit Hyperactivity Disorder (ADHD)
  Interventions:   Drug: SHP465;   Drug: Placebo
  Sponsor:   Shire
  Completed
• Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 Weeks

  NCT02914184

  Condition:   Infections, Rotavirus
  Interventions:   Biological: HRV PCV-free liquid vaccine;   Biological: Rotarix
  Sponsor:   GlaxoSmithKline
  Completed
• A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

  NCT03257644

  Condition:   Atopic Dermatitis
  Intervention:   Drug: Ruxolitinib phosphate cream
  Sponsor:   Incyte Corporation
  Recruiting
• Evaluation of Immunogenicity and Safety of VARIVAX™ Passage Extension 34 (PE34) Process in Children (V210-A03)

  NCT03239873

  Condition:   Varicella
  Interventions:   Biological: VARIVAX™ PE34 Process;   Biological: VARIVAX™ 2016 Commercial Process;   Biological: M-M-R II™
  Sponsor:   Merck Sharp & Dohme Corp.
  Completed
• This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine

  NCT03207750

  Condition:   Rotavirus Infection
  Interventions:   Biological: Rotarix®;   Biological: Pediarix®;   Biological: Hiberix®;   Biological: Prevenar 13®
  Sponsor:   GlaxoSmithKline
  Completed
• 52-104 Week Off-therapy Second Extension to Study CSPP100A2365

  NCT01420068

  Condition:   Hypertension
  Intervention:   Drug: SPP100
  Sponsor:   Noden Pharma
  Completed
• Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children

  NCT03126227

  Condition:   Peanut Allergy
  Interventions:   Biological: AR101;   Biological: Placebo
  Sponsor:   Aimmune Therapeutics, Inc.
  Completed
• Binocular Dig Rush Game Treatment for Amblyopia

  NCT02983552

  Condition:   Amblyopia
  Interventions:   Other: iPad®;   Other: Spectacle correction
  Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
  Recruiting
• A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

  NCT02963766

  Condition:   Type 2 Diabetes
  Interventions:   Drug: Dulaglutide;   Drug: Placebo
  Sponsor:   Eli Lilly and Company
  Recruiting
• Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

  NCT02849626

  Condition:   Partial-Onset or Primary Generalized Tonic-Clonic Seizures
  Intervention:   Drug: Perampanel
  Sponsor:   Eisai Inc.
  Active, not recruiting
• Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

  NCT02828358

  Conditions:   Acute Leukemia of Ambiguous Lineage;   B Acute Lymphoblastic Leukemia;   KMT2A Gene Rearrangement;   Mixed Phenotype Acute Leukemia
  Interventions:   Drug: Azacitidine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisolone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Trial of Overminus Spectacle Therapy for Intermittent Exotropia

  NCT02807350

  Condition:   Intermittent Exotropia
  Interventions:   Device: Overminus treatment;   Device: Non-overminus treatment
  Sponsors:   Jaeb Center for Health Research;   Pediatric Eye Disease Investigator Group;   National Eye Institute (NEI)
  Active, not recruiting
• Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome

  NCT02521493

  Conditions:   Acute Myeloid Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Cytopenia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
  Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A

  NCT02137850

  Conditions:   Congenital Bleeding Disorder;   Haemophilia A
  Intervention:   Drug: turoctocog alfa pegol
  Sponsor:   Novo Nordisk A/S
  Enrolling by invitation
• A Study of the Safety and Effectiveness of Apixaban in Preventing Blood Clots in Children With Leukemia Who Have a Central Venous Catheter and Are Treated With Asparaginase

  NCT02369653

  Conditions:   Lymphoma;   Acute Lymphoblastic Leukemia
  Interventions:   Drug: Apixaban;   Other: No systemic anticoagulant prophylaxis
  Sponsors:   Bristol-Myers Squibb;   Pfizer
  Recruiting
• Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

  NCT02176967

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neuroblastoma
  Interventions:   Drug: Carboplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

  NCT02017964

  Conditions:   Desmoplastic/Nodular Medulloblastoma;   Medulloblastoma;   Medulloblastoma With Extensive Nodularity;   Nevoid Basal Cell Carcinoma Syndrome;   Untreated Childhood Medulloblastoma
  Interventions:   Drug: Carboplatin;   Other: Cognitive Assessment;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• A Trial Investigating the Efficacy and Safety of Insulin Degludec/Insulin Aspart Once Daily Plus Insulin Aspart for the Remaining Meals Versus Insulin Detemir Once or Twice Daily Plus Meal Time Insulin Aspart in Children and Adolescents With Type 1 Diabetes Mellitus

  NCT01835431

  Conditions:   Diabetes;   Diabetes Mellitus, Type 1
  Interventions:   Drug: insulin degludec/insulin aspart;   Drug: insulin aspart;   Drug: insulin detemir
  Sponsor:   Novo Nordisk A/S
  Completed
• Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia

  NCT01460160

  Condition:   Leukemia, Pediatric
  Intervention:   Drug: Dasatinib
  Sponsors:   Bristol-Myers Squibb;   Children's Oncology Group;   EsPhALL
  Active, not recruiting
• A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease

  NCT00606346

  Conditions:   Crohn's Disease;   Ulcerative Colitis;   Indeterminate Colitis;   Inflammatory Bowel Diseases
  Interventions:   Biological: Anti TNF therapy including infliximab;   Drug: No Biologics
  Sponsor:   Janssen Biotech, Inc.
  Active, not recruiting
• Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193

  Conditions:   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Biological: Filgrastim;   Other: Laboratory Biomarker Analysis;   Drug: Lestaurtinib;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Prednisone;   Drug: Therapeutic Hydrocortisone;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

  NCT00499616

  Condition:   Neuroblastoma
  Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride;   Drug: Isotretinoin;   Procedure: Surgery;   Drug: Filgrastim
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

  NCT03845296

  Conditions:   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Loss of Heterozygosity;   Lung Non-Small Cell Squamous Carcinoma;   Recurrent Large Cell Lung Carcinoma;   Recurrent Lung Adenocarcinoma;   Recurrent Lung Non-Small Cell Carcinoma;   Recurrent Non-Squamous Non-Small Cell Lung Carcinoma;   Stage IV Lung Cancer AJCC v8;   Stage IVA Lung Cancer AJCC v8;   Stage IVB Lung Cancer AJCC v8
  Intervention:   Drug: Rucaparib
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Evaluation of Mammographic Breast Density in Participants With Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

  NCT03609021

  Conditions:   Breast Carcinoma;   Estrogen Receptor Negative;   Progesterone Receptor Negative
  Interventions:   Procedure: Screening Mammography;   Procedure: Biospecimen Collection
  Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI)
  Recruiting
• S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

  NCT03091660

  Conditions:   Stage 0 Bladder Urothelial Carcinoma;   Stage 0is Bladder Urothelial Carcinoma;   Stage I Bladder Urothelial Carcinoma
  Interventions:   Biological: BCG Solution;   Biological: BCG Tokyo-172 Strain Solution;   Biological: BCG Tokyo-172 Strain Vaccine;   Other: Laboratory Biomarker Analysis
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer

  NCT02642042

  Conditions:   KRAS Gene Mutation;   Recurrent Lung Non-Small Cell Carcinoma;   Stage IV Lung Non-Small Cell Cancer AJCC v7
  Interventions:   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Trametinib
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

  NCT02180867

  Conditions:   Alveolar Soft Part Sarcoma;   Angiomatoid Fibrous Histiocytoma;   Atypical Fibroxanthoma;   Clear Cell Sarcoma of Soft Tissue;   Epithelioid Malignant Peripheral Nerve Sheath Tumor;   Epithelioid Sarcoma;   Extraskeletal Myxoid Chondrosarcoma;   Extraskeletal Osteosarcoma;   Fibrohistiocytic Neoplasm;   Fibrosarcoma;   Glomus Tumor of the Skin;   Inflammatory Myofibroblastic Tumor;   Intimal Sarcoma;   Leiomyosarcoma;   Liposarcoma;   Low Grade Fibromyxoid Sarcoma;   Low Grade Myofibroblastic Sarcoma;   Malignant Cutaneous Granular Cell Tumor;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Triton Tumor;   Mesenchymal Chondrosarcoma;   Myxofibrosarcoma;   Myxoid Chondrosarcoma;   Myxoinflammatory Fibroblastic Sarcoma;   Nerve Sheath Neoplasm;   PEComa;   Pericytic Neoplasm;   Plexiform Fibrohistiocytic Tumor;   Sclerosing Epithelioid Fibrosarcoma;   Stage IB Soft Tissue Sarcoma AJCC v7;   Stage IIB Soft Tissue Sarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Synovial Sarcoma;   Undifferentiated (Embryonal) Sarcoma;   Undifferentiated High Grade Pleomorphic Sarcoma of Bone
  Interventions:   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Drug: Pazopanib;   Drug: Pazopanib Hydrochloride;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

  NCT01274338

  Conditions:   Melanoma of Unknown Primary;   Recurrent Melanoma;   Stage IIIB Cutaneous Melanoma AJCC v7;   Stage IIIC Cutaneous Melanoma AJCC v7;   Stage IV Cutaneous Melanoma AJCC v6 and v7
  Interventions:   Biological: Ipilimumab;   Other: Quality-of-Life Assessment;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

  NCT00874211

  Conditions:   Breast Cancer;   Lung Cancer;   Metastatic Cancer;   Multiple Myeloma;   Plasma Cell Neoplasm;   Prostate Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
  Intervention:   Procedure: assessment of therapy complications
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Novartis
  Completed
• Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer

  NCT00492778

  Conditions:   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Cisplatin;   Radiation: Intensity-Modulated Radiation Therapy;   Radiation: Internal Radiation Therapy
  Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy

  NCT01598298

  Conditions:   Breast Cancer;   Musculoskeletal Complications;   Pain
  Interventions:   Drug: duloxetine hydrochloride;   Other: placebo
  Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
  Completed
• Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

  NCT03605862

  Conditions:   Enterovirus;   Rhinovirus
  Interventions:   Drug: Nitazoxanide;   Drug: Placebo
  Sponsor:   Romark Laboratories L.C.
  Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

  NCT03422822

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)

  NCT03105479

  Condition:   Clostridium Difficile Infection
  Interventions:   Drug: Cadazolid;   Drug: Vancomycin capsule;   Drug: Vancomycin solution
  Sponsor:   Actelion
  Terminated
• CLUSTER Trial for Outbreak Detection and Response

  NCT04053075

  Condition:   Cluster Detection
  Interventions:   Other: Routine cluster detection;   Other: Enhanced cluster detection
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America (HCA) Healthcare;   Brigham and Women's Hospital;   University of California, Irvine;   Harvard School of Public Health;   Rush University;   Duke University;   University of Massachusetts, Amherst;   University of California, San Francisco;   Cook County Health & Hospitals System;   Centers for Disease Control and Prevention
  Recruiting
• A Study of Oral VT-1161 for the Treatment of Acute Vaginal Candidiasis (Yeast Infection) in Patients With Recurrent Vaginal Candidiasis

  NCT03840616

  Condition:   Recurrent Vulvovaginal Candidiasis
  Interventions:   Drug: VT-1161 150 mg capsule;   Drug: Fluconazole 150 mg;   Other: Placebo
  Sponsor:   Mycovia Pharmaceuticals Inc.
  Recruiting
• An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

  NCT03749447

  Conditions:   Chronic Kidney Diseases;   Alport Syndrome
  Intervention:   Drug: Bardoxolone methyl
  Sponsor:   Reata Pharmaceuticals, Inc.
  Recruiting
• Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

  NCT03575871

  Condition:   Dermatitis, Atopic
  Interventions:   Drug: PF-04965842 100 mg;   Drug: PF-04965842 200 mg;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications

  NCT03381196

  Condition:   Influenza A
  Interventions:   Drug: Pimodivir 600 mg;   Drug: Placebo;   Other: SOC Treatment
  Sponsor:   Janssen Research & Development, LLC
  Recruiting
• Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

  NCT03358147

  Condition:   Asthma
  Interventions:   Drug: GP MDI 28.8 μg;   Drug: GP MDI 14.4 μg;   Drug: GP MDI 7.2 μg;   Drug: Placebo MDI;   Drug: Spiriva Respimat 2.5 μg
  Sponsor:   Pearl Therapeutics, Inc.
  Active, not recruiting
• Mupirocin-Iodophor ICU Decolonization Swap Out Trial

  NCT03140423

  Condition:   Staphylococcus Aureus
  Interventions:   Drug: Arm 1. Routine Care (Mupirocin/CHG);   Drug: Arm 2. Iodophor/CHG Decolonization
  Sponsors:   Harvard Pilgrim Health Care;   Hospital Corporation of America;   University of California, Irvine;   University of Massachusetts, Amherst;   Rush University;   Centers for Disease Control and Prevention
  Active, not recruiting
• CGM Intervention in Teens and Young Adults With Type 1 Diabetes (T1D)

  NCT03263494

  Condition:   Type 1 Diabetes Mellitus
  Intervention:   Device: Continuous Glucose Monitor (CGM)
  Sponsors:   Jaeb Center for Health Research;   The Leona M. and Harry B. Helmsley Charitable Trust
  Active, not recruiting
• SOFI: A Quality Improvement Project to Standardize Use of Intravenous Fluids in Hospitalized Pediatric Patients

  NCT03924674

  Conditions:   Intravenous Fluids;   Fluid and Electrolyte Imbalance;   ADH Inappropriate
  Intervention:   Other: Education, clinical decision support tools
  Sponsors:   Seattle Children's Hospital;   American Academy of Pediatrics
  Active, not recruiting
• Evaluation of Efficacy, Safety and Tolerability of VeraCept IUD

  NCT03633799

  Condition:   Women at Risk for Pregnancy
  Intervention:   Drug: VeraCept
  Sponsors:   Sebela Pharmaceuticals Inc.;   Synteract, Inc.
  Recruiting
• Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

  NCT03533582

  Conditions:   Childhood Hepatocellular Carcinoma;   Childhood Malignant Liver Neoplasm;   Elevated Alpha-Fetoprotein;   Hepatoblastoma;   Hepatocellular Malignant Neoplasm, Not Otherwise Specified;   SMARCB1 Gene Mutation
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Fluorouracil;   Drug: Gemcitabine;   Drug: Irinotecan;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Other: Patient Observation;   Drug: Sorafenib;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• AR101 Real-World Open-Label Extension Study

  NCT03337542

  Condition:   Peanut Allergy
  Intervention:   Biological: AR101
  Sponsor:   Aimmune Therapeutics, Inc.
  Active, not recruiting
• Long-term Safety Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

  NCT03292484

  Condition:   Peanut Allergy
  Intervention:   Biological: AR101
  Sponsor:   Aimmune Therapeutics, Inc.
  Enrolling by invitation
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

  NCT03233204

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Deleterious ATM Gene Mutation;   Deleterious BRCA1 Gene Mutation;   Deleterious BRCA2 Gene Mutation;   Deleterious RAD51C Gene Mutation;   Deleterious RAD51D Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
  Intervention:   Drug: Olaparib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

  NCT03220035

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF NP_004324.2:p.V600X;   Ependymoma;   Ewing Sarcoma;   Hepatoblastoma;   Langerhans Cell Histiocytosis;   Malignant Germ Cell Tumor;   Malignant Glioma;   Osteosarcoma;   Peripheral Primitive Neuroectodermal Tumor;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Rhabdomyosarcoma;   Soft Tissue Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

  NCT03213704

  Conditions:   Advanced Malignant Solid Neoplasm;   NTRK1 Fusion Positive;   NTRK2 Fusion Positive;   NTRK3 Fusion Positive;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Wilms Tumor
  Interventions:   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213691

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   BRAF Gene Mutation;   GNA11 Gene Mutation;   GNAQ Gene Mutation;   Histiocytosis;   HRAS Gene Mutation;   KRAS Gene Mutation;   NF1 Gene Mutation;   NRAS Gene Mutation;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Selumetinib;   Drug: Selumetinib Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213678

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   TSC1 Gene Mutation;   TSC2 Gene Mutation;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Samotolisib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

  NCT03213665

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Hodgkin Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   EZH2 Gain of Function;   EZH2 Gene Mutation;   Histiocytosis;   Loss of BRG1 Protein Expression;   Loss of INI 1 Protein Expression;   Low Grade Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Hodgkin Lymphoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Hodgkin Lymphoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   SMARCA4 Gene Inactivation;   SMARCB1 Gene Inactivation;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Tazemetostat
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

  NCT03213652

  Conditions:   Advanced Malignant Solid Neoplasm;   ALK Fusion Protein Expression;   ALK Gene Mutation;   ALK Gene Translocation;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Histiocytosis;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Refractory Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   ROS1 Fusion Positive;   ROS1 Gene Mutation;   ROS1 Gene Translocation
  Interventions:   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

  NCT03210714

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   FGFR1 Gene Mutation;   FGFR2 Gene Mutation;   FGFR3 Gene Mutation;   FGFR4 Gene Mutation;   Histiocytosis;   Low Grade Glioma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Central Nervous System Neoplasm;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Rhabdoid Tumor;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Wilms Tumor
  Interventions:   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old

  NCT03199053

  Condition:   Diabetes Mellitus, Type 2
  Interventions:   Drug: Dapagliflozin;   Drug: Saxagliptin;   Drug: Placebo
  Sponsor:   AstraZeneca
  Recruiting
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

  NCT03155620

  Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Childhood Langerhans Cell Histiocytosis;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
  Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147

  Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
  Recruiting
• PALISADE Follow-on Study (ARC004)

  NCT02993107

  Condition:   Peanut Allergy
  Intervention:   Biological: AR101
  Sponsor:   Aimmune Therapeutics, Inc.
  Completed
• Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

  NCT02981628

  Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   CD22 Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Recurrent B Lymphoblastic Lymphoma;   Refractory B Acute Lymphoblastic Leukemia;   Refractory B Lymphoblastic Lymphoma
  Interventions:   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Suspended
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049

  Conditions:   B Acute Lymphoblastic Leukemia;   Central Nervous System Leukemia;   Ph-Like Acute Lymphoblastic Leukemia;   Testicular Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dasatinib;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

  NCT02867592

  Conditions:   Adrenal Cortex Carcinoma;   Alveolar Soft Part Sarcoma;   Central Nervous System Neoplasm;   Childhood Clear Cell Sarcoma of Soft Parts;   Clear Cell Sarcoma of Soft Tissue;   Ewing Sarcoma;   Hepatoblastoma;   Hepatocellular Carcinoma;   MITF Positive;   Osteosarcoma;   Recurrent Adrenal Cortex Carcinoma;   Recurrent Alveolar Soft Part Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Hepatoblastoma;   Recurrent Hepatocellular Carcinoma;   Recurrent Malignant Central Nervous System Neoplasm;   Recurrent Malignant Solid Neoplasm;   Recurrent Osteosarcoma;   Recurrent Renal Cell Carcinoma;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Recurrent Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Recurrent Thyroid Gland Medullary Carcinoma;   Refractory Ewing Sarcoma;   Refractory Malignant Central Nervous System Neoplasm;   Refractory Malignant Solid Neoplasm;   Refractory Osteosarcoma;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Refractory Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Renal Cell Carcinoma;   Rhabdomyosarcoma;   Soft Tissue Sarcoma, Excluding Rhabdomyosarcoma;   Solid Neoplasm;   Thyroid Gland Medullary Carcinoma;   Wilms Tumor
  Interventions:   Drug: Cabozantinib;   Drug: Cabozantinib S-malate;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes

  NCT02846545

  Condition:   Diabetes Mellitus, Type 1
  Interventions:   Biological: Golimumab;   Biological: Placebo
  Sponsor:   Janssen Research & Development, LLC
  Active, not recruiting
• An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE)

  NCT02736409

  Condition:   Eosinophilic Esophagitis (EoE)
  Interventions:   Drug: Oral Budesonide Suspension (OBS);   Drug: Placebo
  Sponsor:   Shire
  Active, not recruiting
• Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

  NCT02724579

  Conditions:   CTNNB1 Gene Mutation;   Medulloblastoma;   Wnt Positive
  Interventions:   Drug: Cisplatin;   Drug: Cyclophosphamide;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Radiation: Radiation Therapy;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Neuroblastoma Maintenance Therapy Trial

  NCT02679144

  Condition:   Neuroblastoma
  Intervention:   Drug: Difluoromethylornithine (DFMO)
  Sponsors:   Giselle Sholler;   KC Pharma;   Beat NB Cancer Foundation
  Recruiting
• Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE)

  NCT02635776

  Condition:   Peanut Allergy
  Interventions:   Biological: AR101 powder provided in capsules & sachets;   Biological: Placebo powder provided in capsules & sachets
  Sponsor:   Aimmune Therapeutics, Inc.
  Completed
• A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

  NCT02605837

  Condition:   Eosinophilic Esophagitis (EoE)
  Interventions:   Drug: Oral Budesonide Suspension (OBS);   Drug: Placebo
  Sponsor:   Shire
  Completed
• Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

  NCT02559778

  Condition:   Neuroblastoma
  Interventions:   Drug: Ceritinib;   Drug: dasatinib;   Drug: sorafenib;   Drug: vorinostat;   Drug: DFMO
  Sponsors:   Giselle Sholler;   Dell, Inc.;   Beat NB Cancer Foundation
  Recruiting
• Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma

  NCT02484443

  Conditions:   Metastatic Malignant Neoplasm in the Lung;   Metastatic Osteosarcoma;   Recurrent Osteosarcoma
  Interventions:   Biological: Dinutuximab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Sargramostim
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

  NCT02470091

  Conditions:   Metastatic Osteosarcoma;   Recurrent Osteosarcoma;   Refractory Osteosarcoma;   Stage IV Osteosarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7
  Interventions:   Biological: Denosumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma

  NCT02452554

  Conditions:   Pleuropulmonary Blastoma;   Recurrent Malignant Peripheral Nerve Sheath Tumor;   Recurrent Neuroblastoma;   Recurrent Rhabdomyosarcoma;   Recurrent Synovial Sarcoma;   Wilms Tumor
  Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Lorvotuzumab Mertansine;   Other: Pharmacological Study
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Project: Every Child for Younger Patients With Cancer

  NCT02402244

  Conditions:   Central Nervous System Neoplasm;   Childhood Immature Teratoma;   Childhood Langerhans Cell Histiocytosis;   Childhood Malignant Neoplasm;   Childhood Mature Teratoma;   Congenital Mesoblastic Nephroma;   Desmoid-Type Fibromatosis;   Lymphoproliferative Disorder;   Myeloproliferative Neoplasm;   Stromal Neoplasm
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Medical Chart Review
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia

  NCT02339740

  Condition:   Acute Promyelocytic Leukemia With PML-RARA
  Interventions:   Drug: Arsenic Trioxide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tretinoin
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma

  NCT02306161

  Conditions:   Metastatic Ewing Sarcoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Bone Marrow;   Metastatic Malignant Neoplasm in the Lung;   Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Etoposide Phosphate;   Radiation: External Beam Radiation Therapy;   Biological: Ganitumab;   Drug: Ifosfamide;   Radiation: Stereotactic Radiosurgery;   Procedure: Therapeutic Surgical Procedure;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB or Stage IIIB-IVB Hodgkin Lymphoma

  NCT02166463

  Conditions:   Ann Arbor Stage IIB Hodgkin Lymphoma;   Ann Arbor Stage IIIB Hodgkin Lymphoma;   Ann Arbor Stage IV Hodgkin Lymphoma;   Ann Arbor Stage IVA Hodgkin Lymphoma;   Ann Arbor Stage IVB Hodgkin Lymphoma;   Childhood Hodgkin Lymphoma;   Classic Hodgkin Lymphoma
  Interventions:   Biological: Bleomycin Sulfate;   Drug: Brentuximab Vedotin;   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Pediatric Obesity Weight Evaluation Registry (POWER) Study

  NCT02121132

  Conditions:   Overweight;   Obesity
  Intervention:  
  Sponsors:   Children's Hospital Medical Center, Cincinnati;   Helen DeVos Children's Hospital;   Mayo Clinic;   Duke University;   National Association of Children's Hospitals and Related Institutions (NACHRI);   Penn State Hershey Children's Hospital;   UNM Children's Hospital;   University of Illinois College of Medicine at Peoria;   Children's Hospital Los Angeles;   Connecticut Children's Medical Center;   Children's Hospital of San Antonio;   Ann & Robert H Lurie Children's Hospital of Chicago;   Children's Mercy Hospital Kansas City;   Arkansas Children's Hospital Research Institute;   Florida Hospital for Children;   UCSF Benioff Children’s Hospital Oakland;   University of Oklahoma;   Barbara Bush Children's Hospital at Maine Medical Center;   Seattle Children's Hospital;   Eastern Maine Medical Center;   University of Florida;   University of California, Los Angeles;   Gramercy Pediatrics;   St. Louis Children's Hospital;   Children's Hospital at Dartmouth (CHaD) Pediatric Lipid and Weight Management Center;   University of Alabama at Birmingham;   University of Oklahoma-Tulsa;   Fit Kids of Arizona;   University of Kentucky;   Orlando Health/Arnold Palmer Hospital Center for Digestive Health and Nutrition;   Cleveland Clinic Children's
  Recruiting
• Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

  NCT02112916

  Conditions:   Adult T Acute Lymphoblastic Leukemia;   Ann Arbor Stage II Adult Lymphoblastic Lymphoma;   Ann Arbor Stage II Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage III Adult Lymphoblastic Lymphoma;   Ann Arbor Stage III Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage IV Adult Lymphoblastic Lymphoma;   Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma;   Childhood T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Drug: Bortezomib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Hydrocortisone Sodium Succinate;   Drug: Ifosfamide;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

  NCT02101853

  Condition:   B Acute Lymphoblastic Leukemia
  Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Asparaginase;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Mitoxantrone Hydrochloride;   Drug: Pegaspargase;   Other: Pharmacological Study;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Recruiting
• Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

  NCT01979536

  Conditions:   Anaplastic Large Cell Lymphoma, ALK-Positive;   Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   CD30-Positive Neoplastic Cells Present
  Interventions:   Drug: Brentuximab Vedotin;   Drug: Crizotinib;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate
  Sponsor:   National Cancer Institute (NCI)
  Suspended
• Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

  NCT01793233

  Conditions:   Acute Lymphoblastic Leukemia;   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   Ann Arbor Stage I Adult Burkitt Lymphoma;   Ann Arbor Stage I Adult Hodgkin Lymphoma;   Ann Arbor Stage I Adult Immunoblastic Lymphoma;   Ann Arbor Stage I Adult Lymphoblastic Lymphoma;   Ann Arbor Stage I Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage I Childhood Burkitt Lymphoma;   Ann Arbor Stage I Childhood Hodgkin Lymphoma;   Ann Arbor Stage I Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage I Grade 1 Follicular Lymphoma;   Ann Arbor Stage I Grade 2 Follicular Lymphoma;   Ann Arbor Stage I Grade 3 Follicular Lymphoma;   Ann Arbor Stage I Mantle Cell Lymphoma;   Ann Arbor Stage I Marginal Zone Lymphoma;   Ann Arbor Stage I Non-Hodgkin Lymphoma;   Ann Arbor Stage I Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage I Small Lymphocytic Lymphoma;   Ann Arbor Stage II Adult Contiguous Immunoblastic Lymphoma;   Ann Arbor Stage II Adult Hodgkin Lymphoma;   Ann Arbor Stage II Adult Non-Contiguous Immunoblastic Lymphoma;   Ann Arbor Stage II Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage II Childhood Burkitt Lymphoma;   Ann Arbor Stage II Childhood Hodgkin Lymphoma;   Ann Arbor Stage II Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage II Contiguous Adult Burkitt Lymphoma;   Ann Arbor Stage II Contiguous Adult Lymphoblastic Lymphoma;   Ann Arbor Stage II Contiguous Mantle Cell Lymphoma;   Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma;   Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Ann Arbor Stage II Marginal Zone Lymphoma;   Ann Arbor Stage II Non-Contiguous Adult Burkitt Lymphoma;   Ann Arbor Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Ann Arbor Stage II Non-Contiguous Mantle Cell Lymphoma;   Ann Arbor Stage II Non-Hodgkin Lymphoma;   Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage II Small Lymphocytic Lymphoma;   Ann Arbor Stage III Adult Burkitt Lymphoma;   Ann Arbor Stage III Adult Hodgkin Lymphoma;   Ann Arbor Stage III Adult Immunoblastic Lymphoma;   Ann Arbor Stage III Adult Lymphoblastic Lymphoma;   Ann Arbor Stage III Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage III Childhood Burkitt Lymphoma;   Ann Arbor Stage III Childhood Hodgkin Lymphoma;   Ann Arbor Stage III Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Grade 3 Follicular Lymphoma;   Ann Arbor Stage III Mantle Cell Lymphoma;   Ann Arbor Stage III Marginal Zone Lymphoma;   Ann Arbor Stage III Non-Hodgkin Lymphoma;   Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage III Small Lymphocytic Lymphoma;   Ann Arbor Stage IV Adult Burkitt Lymphoma;   Ann Arbor Stage IV Adult Hodgkin Lymphoma;   Ann Arbor Stage IV Adult Immunoblastic Lymphoma;   Ann Arbor Stage IV Adult Lymphoblastic Lymphoma;   Ann Arbor Stage IV Adult T-Cell Leukemia/Lymphoma;   Ann Arbor Stage IV Childhood Burkitt Lymphoma;   Ann Arbor Stage IV Childhood Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Grade 3 Follicular Lymphoma;   Ann Arbor Stage IV Mantle Cell Lymphoma;   Ann Arbor Stage IV Marginal Zone Lymphoma;   Ann Arbor Stage IV Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma;   Ann Arbor Stage IV Small Lymphocytic Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Lymphoma;   Childhood Nasal Type Extranodal NK/T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Hairy Cell Leukemia;   Hepatosplenic T-Cell Lymphoma;   Intraocular Lymphoma;   Lymphomatous Involvement of Non-Cutaneous Extranodal Site;   Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Nodal Marginal Zone Lymphoma;   Non-Hodgkin Lymphoma;   Primary Cutaneous B-Cell Non-Hodgkin Lymphoma;   Progressive Hairy Cell Leukemia Initial Treatment;   Small Intestinal Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage II Chronic Lymphocytic Leukemia;   Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage III Chronic Lymphocytic Leukemia;   Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7;   Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7;   T-Cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Hairy Cell Leukemia;   Waldenstrom Macroglobulinemia
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

  NCT01602666

  Conditions:   Central Nervous System Nongerminomatous Germ Cell Tumor;   Childhood Central Nervous System Germinoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Radiation: Intensity-Modulated Radiation Therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149

  Conditions:   Neurofibromatosis Type 1;   Recurrent Childhood Pilocytic Astrocytoma;   Recurrent Childhood Visual Pathway Glioma
  Interventions:   Drug: Lenalidomide;   Other: Pharmacological Study
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981

  Conditions:   Acute Myeloid Leukemia;   Leukemia Cutis;   Myeloid Neoplasm;   Myeloid Sarcoma;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Myeloid Neoplasm
  Interventions:   Drug: Asparaginase;   Drug: Bortezomib;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Sorafenib Tosylate
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906

  Conditions:   Non-Metastatic Extraskeletal Ewing Sarcoma;   Peripheral Primitive Neuroectodermal Tumor of Bone;   Peripheral Primitive Neuroectodermal Tumor of Soft Tissues
  Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Topotecan Hydrochloride;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus

  NCT00137969

  Condition:   Lupus Erythematosus, Systemic
  Interventions:   Drug: Rituximab;   Drug: Placebo;   Drug: Prednisone;   Drug: Acetaminophen;   Drug: Diphenhydramine
  Sponsor:   Genentech, Inc.
  Completed
• Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930

  Conditions:   Acute Lymphoblastic Leukemia;   Adult B Lymphoblastic Lymphoma;   Ann Arbor Stage I B Lymphoblastic Lymphoma;   Ann Arbor Stage II B Lymphoblastic Lymphoma;   Childhood B Acute Lymphoblastic Leukemia;   Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Childhood B Lymphoblastic Lymphoma;   Down Syndrome;   Hypodiploid B Acute Lymphoblastic Leukemia;   Intrachromosomal Amplification of Chromosome 21;   Philadelphia Chromosome Positive;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
  Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma

  NCT01189266

  Conditions:   Anaplastic Astrocytoma;   Anaplastic Oligoastrocytoma;   Brain Stem Glioma;   Childhood Glioblastoma;   Giant Cell Glioblastoma;   Gliosarcoma;   Untreated Childhood Anaplastic Astrocytoma;   Untreated Childhood Anaplastic Oligoastrocytoma;   Untreated Childhood Brain Stem Glioma;   Untreated Childhood Giant Cell Glioblastoma;   Untreated Childhood Gliosarcoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Vorinostat
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368

  Conditions:   Cellular Ependymoma;   Childhood Anaplastic Ependymoma;   Childhood Infratentorial Ependymoma;   Childhood Supratentorial Ependymoma;   Clear Cell Ependymoma;   Ependymoma;   Newly Diagnosed Childhood Ependymoma;   Papillary Ependymoma
  Interventions:   Radiation: 3-Dimensional Conformal Radiation Therapy;   Drug: Carboplatin;   Drug: Cisplatin;   Other: Clinical Observation;   Drug: Cyclophosphamide;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vincristine Sulfate Liposome
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

  NCT00995150

  Condition:   Contraception
  Interventions:   Drug: LNG20;   Drug: Mirena
  Sponsor:   Medicines360
  Active, not recruiting
• Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460

  Conditions:   Alpha Fetoprotein Increased;   PRETEXT Stage 1 Hepatoblastoma;   PRETEXT Stage 2 Hepatoblastoma;   PRETEXT Stage 3 Hepatoblastoma;   PRETEXT Stage 4 Hepatoblastoma
  Interventions:   Drug: Cisplatin;   Drug: Dexrazoxane;   Drug: Doxorubicin Hydrochloride;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Procedure: Liver Transplantation;   Drug: Temsirolimus;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting
• Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009

  Conditions:   Adult Kidney Wilms Tumor;   Beckwith-Wiedemann Syndrome;   Childhood Kidney Wilms Tumor;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Hemihypertrophy;   Rhabdoid Tumor of the Kidney;   Stage I Kidney Wilms Tumor;   Stage II Kidney Wilms Tumor;   Stage III Kidney Wilms Tumor;   Stage IV Kidney Wilms Tumor;   Stage V Kidney Wilms Tumor
  Interventions:   Biological: Dactinomycin;   Drug: Doxorubicin Hydrochloride;   Radiation: Radiation Therapy;   Procedure: Therapeutic Conventional Surgery;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma

  NCT00904241

  Conditions:   Ganglioneuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4 Neuroblastoma;   Stage 4S Neuroblastoma
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Study of Kidney Tumors in Younger Patients

  NCT00898365

  Conditions:   Clear Cell Sarcoma of the Kidney;   Congenital Mesoblastic Nephroma;   Diffuse Hyperplastic Perilobar Nephroblastomatosis;   Rhabdoid Tumor of the Kidney;   Stage I Kidney Wilms Tumor;   Stage I Renal Cell Cancer AJCC v6 and v7;   Stage II Kidney Wilms Tumor;   Stage II Renal Cell Cancer AJCC v7;   Stage III Kidney Wilms Tumor;   Stage III Renal Cell Cancer AJCC v7;   Stage IV Kidney Wilms Tumor;   Stage IV Renal Cell Cancer AJCC v7;   Stage V Kidney Wilms Tumor
  Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005

  Conditions:   T Acute Lymphoblastic Leukemia;   T Lymphoblastic Lymphoma
  Interventions:   Drug: Asparaginase;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Nelarabine;   Drug: Pegaspargase;   Drug: Prednisone;   Radiation: Radiation Therapy;   Drug: Thioguanine;   Drug: Vincristine Sulfate
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma

  NCT00392327

  Conditions:   Anaplastic Medulloblastoma;   Medulloblastoma;   Untreated Childhood Medulloblastoma
  Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Isotretinoin;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Active, not recruiting
• Radiation Therapy in Treating Young Patients With Gliomas

  NCT00238264

  Conditions:   Brain Tumor;   Central Nervous System Tumor
  Intervention:   Radiation: radiation therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735

  Condition:   Untreated Childhood Medulloblastoma
  Interventions:   Drug: Cisplatin;   Radiation: Craniospinal Irradiation;   Drug: Cyclophosphamide;   Radiation: Involved-Field Radiation Therapy;   Other: Laboratory Biomarker Analysis;   Drug: Lomustine;   Other: Quality-of-Life Assessment;   Radiation: Radiation Therapy;   Drug: Vincristine Sulfate
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

  NCT00082745

  Conditions:   Cancer Survivor;   Cardiovascular Complication;   Childhood Malignant Neoplasm
  Interventions:   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

  NCT00027846

  Conditions:   Brain Tumor;   Central Nervous System Tumor
  Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Radiation: radiation therapy;   Drug: Mesna;   Procedure: therapeutic conventional surgery
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

  NCT00004228

  Condition:   Lymphoma
  Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• Overnight Closed Loop Study in U.S.

  NCT01857973

  Condition:   Type 1 Diabetes
  Intervention:   Device: Hybrid Closed Loop
  Sponsor:   Medtronic Diabetes
  Completed
• A Phase III Study of Efficacy and Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.

  NCT03580356

  Condition:   Chronic Spontaneous Urticaria
  Interventions:   Biological: Ligelizumab;   Biological: Omalizumab;   Other: Placebo
  Sponsor:   Novartis Pharmaceuticals
  Recruiting
• Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

  NCT03989206

  Condition:   Moderate-to-Severe Atopic Dermatitis
  Intervention:   Drug: Nemolizumab
  Sponsor:   Galderma R&D
  Not yet recruiting
• Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

  NCT03987620

  Condition:   Candida Vulvovaginitis
  Interventions:   Drug: Ibrexafungerp;   Drug: Placebo
  Sponsors:   Scynexis, Inc.;   PPD
  Recruiting
• Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

  NCT03985943

  Condition:   Moderate-to-Severe Atopic Dermatitis
  Interventions:   Drug: Placebo;   Drug: Nemolizumab
  Sponsor:   Galderma R&D
  Recruiting
• Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System

  NCT03959423

  Condition:   Type 1 Diabetes Mellitus
  Intervention:   Device: AHCL insulin pump system
  Sponsor:   Medtronic Diabetes
  Recruiting
• A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

  NCT03927716

  Condition:   Molluscum Contagiosum
  Interventions:   Drug: SB206 12%;   Drug: Placebo
  Sponsors:   Novan, Inc.;   Synteract, Inc.
  Recruiting
• Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

  NCT03893448

  Conditions:   Pneumococcal Infections;   Pneumococcal Vaccines
  Interventions:   Biological: V114;   Biological: Prevnar 13™;   Biological: RotaTeq™;   Biological: Pentacel™;   Biological: RECOMBIVAX HB™;   Biological: VAQTA™;   Biological: M-M-R™;   Biological: VARIVAX™;   Biological: HIBERIX™
  Sponsor:   Merck Sharp & Dohme Corp.
  Recruiting
• Study in Subjects With Moderate Atopic Dermatitis

  NCT03859986

  Condition:   Atopic Dermatitis Eczema
  Interventions:   Drug: ALX-101 Gel Vehicle;   Drug: ALX-101 Gel 5%
  Sponsor:   Ralexar Therapeutics, Inc.
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma

  NCT03847896

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Budesonide metered-dose inhaler 160 µg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg;   Combination Product: Placebo metered-dose inhaler
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

  NCT03769090

  Condition:   Asthma
  Interventions:   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg;   Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg;   Combination Product: Albuterol sulfate metered-dose inhaler 180 μg
  Sponsor:   Bond Avillion 2 Development LP
  Recruiting
• TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis

  NCT03745651

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Ruxolitinib cream;   Drug: Vehicle cream
  Sponsor:   Incyte Corporation
  Recruiting
• PF-06651600 for the Treatment of Alopecia Areata

  NCT03732807

  Condition:   Alopecia Areata
  Interventions:   Drug: PF-06651600 Induction Dose;   Drug: PF-06651600 Maintenance Dose #1;   Drug: PF-06651600 Maintenance Dose #2;   Drug: PF-06651600 Maintenance Dose #3;   Drug: Placebo
  Sponsor:   Pfizer
  Recruiting
• Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma

  NCT03706079

  Condition:   Asthma
  Interventions:   Biological: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Enrolling by invitation
• Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

  NCT03664752

  Condition:   Acne Vulgaris
  Interventions:   Drug: IDP-120 Gel;   Drug: IDP-120 Vehicle Gel
  Sponsor:   Bausch Health Americas, Inc.
  Recruiting
• An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

  NCT03259633

  Condition:   NF type1 With Inoperable Plexiform Neurofibromas
  Intervention:   Drug: Selumetinib
  Sponsor:   AstraZeneca
  Available
• A Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

  NCT03607422

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT03568318

  Condition:   Atopic Dermatitis
  Interventions:   Drug: Upadacitinib;   Drug: Placebo for Upadacitinib;   Drug: Topical corticosteroids (TCS)
  Sponsor:   AbbVie
  Recruiting
• A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Subjects With an F508del CFTR Mutation

  NCT03537651

  Condition:   Cystic Fibrosis
  Interventions:   Drug: TEZ;   Drug: IVA
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Active, not recruiting
• A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy

  NCT03447262

  Condition:   Cystic Fibrosis
  Interventions:   Drug: VX-659;   Drug: TEZ;   Drug: IVA
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Active, not recruiting
• A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

  NCT03447249

  Condition:   Cystic Fibrosis
  Interventions:   Drug: VX-659;   Drug: TEZ;   Drug: IVA;   Drug: Matched Placebos
  Sponsor:   Vertex Pharmaceuticals Incorporated
  Completed
• Safety and Efficacy of TRx0237 in Subjects With Early Alzheimer's Disease

  NCT03446001

  Condition:   Alzheimer Disease
  Interventions:   Drug: TRx0237 8 mg/day;   Drug: Placebo;   Drug: TRx0237 16 mg/day
  Sponsor:   TauRx Therapeutics Ltd
  Recruiting
• Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma

  NCT03347279

  Condition:   Asthma
  Interventions:   Biological: Experimental: Tezepelumab;   Other: Placebo
  Sponsors:   AstraZeneca;   Amgen
  Recruiting
• Continuous Monitoring and Control of Hypoglycemia

  NCT03340831

  Condition:   Diabetes
  Intervention:   Device: Continuous Glucose Monitoring (CGM)
  Sponsor:   DexCom, Inc.
  Recruiting
• Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With Epilepsy

  NCT03208660

  Condition:   Epilepsy
  Intervention:   Drug: Fycompa
  Sponsor:   Eisai Inc.
  Completed
• Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)

  NCT03189875

  Condition:   Systemic Lupus Erythematosus
  Intervention:   Other: Standard of Care
  Sponsor:   AstraZeneca
  Recruiting
• A Phase 3, Double-Blind 2 Arm Study in the Treatment of Acne Vulgaris

  NCT03168321

  Condition:   Acne Vulgaris
  Interventions:   Drug: IDP-123 Lotion;   Drug: IDP-123 Vehicle Lotion
  Sponsor:   Bausch Health Americas, Inc.
  Completed
• Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

  NCT02998554

  Condition:   Adenoviral Conjunctivitis
  Interventions:   Drug: SHP640;   Drug: Placebo
  Sponsor:   Shire
  Terminated
• 3T MRI CIED Post-Approval Study

  NCT02969395

  Condition:   Cardiac Rhythm Disorder
  Intervention:  
  Sponsor:   Medtronic
  Recruiting
• LEADERS FREE II: BioFreedom™ Pivotal Study

  NCT02843633

  Conditions:   Acute Coronary Syndrome;   High Bleeding Risk
  Interventions:   Device: BioFreedom™ Drug Coated Coronary Stent System;   Drug: Dual Antiplatelet Therapy
  Sponsor:   Biosensors Europe SA
  Active, not recruiting
• Study of Perampanel as Adjunctive Treatment for Inadequately Controlled Seizures Associated With Lennox-Gastaut Syndrome

  NCT02834793

  Condition:   Lennox-Gastaut Syndrome (LGS)
  Interventions:   Drug: Placebo;   Drug: Perampanel
  Sponsor:   Eisai Inc.
  Recruiting
• Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home

  NCT02748018

  Condition:   Type 1 Diabetes
  Interventions:   Device: 670G Insulin Pump;   Device: Subject's Current Diabetes Therapy
  Sponsor:   Medtronic Diabetes
  Recruiting
• Assessment of the Embolization of Neurovascular Lesions Using the Penumbra Smart Coil

  NCT02729740

  Condition:   Intracranial Aneurysm
  Interventions:   Device: Penumbra Smart Coil;   Device: Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)
  Sponsor:   Penumbra Inc.
  Active, not recruiting
• Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With CF

  NCT02677701

  Condition:   Cystic Fibrosis
  Interventions:   Drug: azithromycin;   Drug: placebo (for azithromycin);   Drug: inhaled tobramycin
  Sponsors:   Seattle Children's Hospital;   National Heart, Lung, and Blood Institute (NHLBI);   Cystic Fibrosis Foundation;   CF Therapeutics Development Network Coordinating Center
  Recruiting
• Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

  NCT02531126

  Condition:   Ulcerative Colitis
  Intervention:   Drug: RPC1063
  Sponsor:   Celgene
  Recruiting
• A Study With SAGE-547 for Super-Refractory Status Epilepticus

  NCT02477618

  Condition:   Super-Refractory Status Epilepticus
  Interventions:   Drug: SAGE-547;   Drug: Placebo
  Sponsor:   Sage Therapeutics
  Completed
• Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

  NCT02435992

  Condition:   Ulcerative Colitis
  Interventions:   Drug: RPC1063;   Drug: Placebo
  Sponsor:   Celgene
  Recruiting
• Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic Clonic Seizures

  NCT02408549

  Condition:   Epilepsy
  Interventions:   Drug: Lacosamide Tablet;   Drug: Lasosamide Oral Solution
  Sponsor:   UCB BIOSCIENCES, Inc.
  Active, not recruiting
• A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications

  NCT02408523

  Condition:   Epilepsy
  Interventions:   Drug: Lacosamide Tablet;   Drug: Lasosamide Oral Solution;   Other: Placebo Tablet;   Other: Placebo Oral Solution
  Sponsors:   UCB BIOSCIENCES, Inc.;   Pharmaceutical Research Associates
  Completed
• Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles

  NCT02269241

  Condition:   Contraception
  Intervention:   Drug: LF111 (drospirenone)
  Sponsors:   Laboratories Leon Farma, S.A.;   Chemo France
  Completed
• Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

  NCT02134028

  Condition:   Asthma
  Intervention:   Drug: dupilumab SAR231893 (REGN668)
  Sponsors:   Sanofi;   Regeneron Pharmaceuticals
  Active, not recruiting
• Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

  NCT00513695

  Conditions:   Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
  Interventions:   Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
  Sponsors:   University of Washington;   National Cancer Institute (NCI)
  Completed
• Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use

  NCT01109316

  Condition:   Diabetes Mellitus, Type 1
  Interventions:   Drug: Insulin lispro 2 day reservoir in-use;   Drug: Insulin lispro 6 day reservoir in-use;   Drug: Insulin aspart 6 day reservoir in-use
  Sponsor:   Eli Lilly and Company
  Completed
• Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma

  NCT01767194

  Conditions:   Ganglioneuroblastoma;   Recurrent Neuroblastoma
  Interventions:   Biological: Dinutuximab;   Drug: Irinotecan Hydrochloride;   Other: Laboratory Biomarker Analysis;   Biological: Sargramostim;   Drug: Temozolomide;   Drug: Temsirolimus
  Sponsor:   National Cancer Institute (NCI)
  Completed
• Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

  NCT01529034

  Condition:   Epilepsy
  Intervention:   Drug: USL261
  Sponsor:   Proximagen, LLC
  Terminated
• Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters

  NCT01390220

  Condition:   Epilepsy
  Interventions:   Drug: USL261;   Drug: Placebo
  Sponsor:   Proximagen, LLC
  Terminated
• Brivaracetam Safety and Efficacy Follow-up Study in Subjects With Epilepsy

  NCT01339559

  Condition:   Epilepsy
  Intervention:   Drug: Brivaracetam
  Sponsor:   UCB BIOSCIENCES, Inc.
  Completed
• Web Based Orthopaedic Sports Medicine Registry

  NCT01191151

  Conditions:   Degenerative and Traumatic Pathology of the Knee;   Degenerative and Traumatic Pathology of the Shoulder and Elbow;   Degenerative and Traumatic Pathology of the Foot and Ankle;   Degenerative and Traumatic Pathology of the Hand and Wrist;   Degenerative and Traumatic Pathology of the Hip
  Intervention:  
  Sponsor:   Arthrex, Inc.
  Recruiting
• Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

  NCT01109004

  Condition:   Multiple Myeloma
  Interventions:   Drug: Lenalidomide;   Drug: lenalidomide, bortezomib and dexamethasone
  Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
  Completed
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

  NCT01039376

  Condition:   Leukaemia, Lymphocytic, Chronic
  Interventions:   Biological: Ofatumumab;   Other: Observation
  Sponsor:   Novartis Pharmaceuticals
  Terminated
• Longitudinal Surveillance Registry (LSR) of ACUITY Spiral

  NCT00955708

  Condition:   Heart Failure
  Intervention:   Device: ACUITY Spiral Left Ventricular Lead
  Sponsor:   Boston Scientific Corporation
  Terminated
• Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma

  NCT00900250

  Conditions:   Ann Arbor Stage I Childhood Hodgkin Lymphoma;   Ann Arbor Stage II Childhood Hodgkin Lymphoma;   Ann Arbor Stage III Childhood Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Hodgkin Lymphoma;   Refractory Childhood Hodgkin Lymphoma
  Intervention:   Other: Cytology Specimen Collection Procedure
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Completed
• A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

  NCT00781612

  Condition:   Neoplasm Metastasis
  Interventions:   Drug: Docetaxel;   Drug: Paclitaxel;   Drug: Pertuzumab;   Drug: Trastuzumab;   Drug: Trastuzumab Emtansine
  Sponsors:   Genentech, Inc.;   Hoffmann-La Roche
  Recruiting
• Neuropsychological and Behavioral Testing in Younger Patients With Cancer

  NCT00772200

  Conditions:   Childhood Malignant Neoplasm;   Cognitive Side Effects of Cancer Therapy
  Interventions:   Procedure: Cognitive Assessment;   Other: Quality-of-Life Assessment
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  NCT00736749

  Conditions:   Acute Lymphoblastic Leukemia;   Brain Neoplasm;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Osteosarcoma;   Rhabdomyosarcoma
  Interventions:   Procedure: Assessment of Therapy Complications;   Other: Questionnaire Administration
  Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
  Recruiting
• Multicenter ACL Revision Study (MARS)

  NCT00625885

  Condition:   Rupture of Anterior Cruciate Ligament
  Intervention:  
  Sponsors:   Vanderbilt University;   Vanderbilt University Medical Center;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
  Active, not recruiting
• Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

  NCT00569127

  Conditions:   Atypical Carcinoid Tumor;   Carcinoid Tumor;   Colorectal Neuroendocrine Tumor G1;   Gastric Neuroendocrine Tumor G1;   Neuroendocrine Neoplasm
  Interventions:   Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Drug: Octreotide Acetate;   Biological: Recombinant Interferon Alfa-2b
  Sponsor:   National Cancer Institute (NCI)
  Active, not recruiting